GSK Nov 2024 48.000 put
| Previous close | 6.10 |
| Open | 6.10 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 48.00 |
| Expiry date | 2024-11-15 |
| Day's range | 6.10 - 6.10 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Fool.co.uk3 legendary FTSE 100 dividend stocks I’d buy for passive income today
With at least 30 years of continuous dividend payouts, these FTSE 100 stocks look like good choices for passive income, says Roland Head. The post 3 legendary FTSE 100 dividend stocks I’d buy for passive income today appeared first on The Motley Fool UK.
Simply Wall St.GSK First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GSK ( LON:GSK ) First Quarter 2024 Results Key Financial Results Revenue: UK£7.36b (up 5.9% from 1Q 2023). Net income...
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
